Cargando…
The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial rev...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466859/ https://www.ncbi.nlm.nih.gov/pubmed/32934890 http://dx.doi.org/10.1080/2162402X.2020.1796003 |